JP2006519199A - 2型糖尿病およびアテローム性動脈硬化症の治療のためのpparモジュレーターとしての4−(3−(2−フェニル−オキサゾール−4−イルメトキシ)−シクロヘキシルオキシ)−ブタン酸誘導体および関連化合物 - Google Patents
2型糖尿病およびアテローム性動脈硬化症の治療のためのpparモジュレーターとしての4−(3−(2−フェニル−オキサゾール−4−イルメトキシ)−シクロヘキシルオキシ)−ブタン酸誘導体および関連化合物 Download PDFInfo
- Publication number
- JP2006519199A JP2006519199A JP2006501892A JP2006501892A JP2006519199A JP 2006519199 A JP2006519199 A JP 2006519199A JP 2006501892 A JP2006501892 A JP 2006501892A JP 2006501892 A JP2006501892 A JP 2006501892A JP 2006519199 A JP2006519199 A JP 2006519199A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- ylmethoxy
- cyclohexyloxy
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 176
- 238000011282 treatment Methods 0.000 title claims abstract description 22
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims description 8
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title description 27
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title description 27
- 201000001320 Atherosclerosis Diseases 0.000 title description 5
- MSZHFMAFAHIHRC-UHFFFAOYSA-N 4-[3-[(2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxybutanoic acid Chemical class C1C(OCCCC(=O)O)CCCC1OCC1=COC(C=2C=CC=CC=2)=N1 MSZHFMAFAHIHRC-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 6
- 239000008103 glucose Substances 0.000 claims abstract description 6
- 230000004129 fatty acid metabolism Effects 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 78
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229940125708 antidiabetic agent Drugs 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 13
- 239000002253 acid Substances 0.000 abstract description 11
- 102000004877 Insulin Human genes 0.000 abstract description 8
- 108090001061 Insulin Proteins 0.000 abstract description 8
- 229940125396 insulin Drugs 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 125000004350 aryl cycloalkyl group Chemical group 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 132
- -1 cyclohexane-1,3-diyl Chemical group 0.000 description 126
- 238000006243 chemical reaction Methods 0.000 description 95
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 73
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 62
- 239000000243 solution Substances 0.000 description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 45
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 37
- 239000002904 solvent Substances 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 32
- 239000012074 organic phase Substances 0.000 description 32
- 238000003786 synthesis reaction Methods 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- 102000023984 PPAR alpha Human genes 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 239000004480 active ingredient Substances 0.000 description 25
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- 108010016731 PPAR gamma Proteins 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 21
- 235000019260 propionic acid Nutrition 0.000 description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 239000000556 agonist Substances 0.000 description 20
- 108060001084 Luciferase Proteins 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- BCKQCTMFFSSHIB-UHFFFAOYSA-N CC1=CC=C(C=C1)C2=CC(=C(N2)C3=CC=CC=C3)CI Chemical compound CC1=CC=C(C=C1)C2=CC(=C(N2)C3=CC=CC=C3)CI BCKQCTMFFSSHIB-UHFFFAOYSA-N 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 239000012230 colorless oil Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 239000005089 Luciferase Substances 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 16
- 229910000104 sodium hydride Inorganic materials 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 102000000536 PPAR gamma Human genes 0.000 description 14
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 14
- FSEUPUDHEBLWJY-HWKANZROSA-N diacetylmonoxime Chemical compound CC(=O)C(\C)=N\O FSEUPUDHEBLWJY-HWKANZROSA-N 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 239000012312 sodium hydride Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- 239000000725 suspension Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000004146 Propane-1,2-diol Substances 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 229960004063 propylene glycol Drugs 0.000 description 11
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 11
- 108010028924 PPAR alpha Proteins 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 235000013772 propylene glycol Nutrition 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 102100039556 Galectin-4 Human genes 0.000 description 9
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000012285 osmium tetroxide Substances 0.000 description 9
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- BNCNAQNTIYCMGB-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methylphenyl)-5-phenyl-1,3-oxazole Chemical compound C1=CC(C)=CC=C1C1=NC(CI)=C(C=2C=CC=CC=2)O1 BNCNAQNTIYCMGB-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CJXNLKIWHBTWMM-UHFFFAOYSA-N 4-(iodomethyl)-1,3-oxazole Chemical compound ICC1=COC=N1 CJXNLKIWHBTWMM-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 208000001126 Keratosis Diseases 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 6
- 101100072644 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) INO2 gene Proteins 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 6
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
- 239000012973 diazabicyclooctane Substances 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 6
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- NFWPTDKJPGHAIQ-UHFFFAOYSA-N 2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound OC(=O)C(C)OCC1=CC=C(C(F)(F)F)C=C1 NFWPTDKJPGHAIQ-UHFFFAOYSA-N 0.000 description 5
- DQFNFCZJCTWYGP-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methylphenyl)-5-propan-2-yl-1,3-oxazole Chemical compound ICC1=C(C(C)C)OC(C=2C=CC(C)=CC=2)=N1 DQFNFCZJCTWYGP-UHFFFAOYSA-N 0.000 description 5
- LAKXJTRDJPBSAS-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=C(C=CC=2)C(F)(F)F)=N1 LAKXJTRDJPBSAS-UHFFFAOYSA-N 0.000 description 5
- 206010020649 Hyperkeratosis Diseases 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 229940100389 Sulfonylurea Drugs 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- NTMNMWBNRDKKEE-UHFFFAOYSA-N 2-(2,4-dimethylphenyl)-4-(iodomethyl)-5-methyl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C(=CC(C)=CC=2)C)=N1 NTMNMWBNRDKKEE-UHFFFAOYSA-N 0.000 description 4
- ZVJBPHMCBRHVEV-UHFFFAOYSA-N 2-hydroxyiminopentan-3-one Chemical compound CCC(=O)C(C)=NO ZVJBPHMCBRHVEV-UHFFFAOYSA-N 0.000 description 4
- FTGLOGXZTCJWQV-RCCQNZRSSA-N 3-[(1r,3s)-3-[[5-ethyl-2-(3-methoxyphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C=C(OC)C=CC=2)=N1 FTGLOGXZTCJWQV-RCCQNZRSSA-N 0.000 description 4
- YXXSKPPRENBIBF-GPTJOGTASA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=C(C(F)(F)F)C=C1 YXXSKPPRENBIBF-GPTJOGTASA-N 0.000 description 4
- JEMQSYWUSRUZQU-UHFFFAOYSA-N 3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexan-1-ol Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC1CCCC(O)C1 JEMQSYWUSRUZQU-UHFFFAOYSA-N 0.000 description 4
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical group COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 4
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 4
- AONKVWHDUVHQSZ-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-(4-methylphenyl)-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC(C)=CC=2)=N1 AONKVWHDUVHQSZ-UHFFFAOYSA-N 0.000 description 4
- QGKGLJHQIRRWES-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-(4-propan-2-ylphenyl)-1,3-oxazole Chemical compound C1=CC(C(C)C)=CC=C1C1=NC(CI)=C(C)O1 QGKGLJHQIRRWES-UHFFFAOYSA-N 0.000 description 4
- WZOMSQRBEXCMRP-UHFFFAOYSA-N 5-ethyl-4-(iodomethyl)-2-(3-methoxyphenyl)-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C=C(OC)C=CC=2)=N1 WZOMSQRBEXCMRP-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 108090000331 Firefly luciferases Proteins 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 108010084455 Zeocin Proteins 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- STXQYTGSIQCKFA-UHFFFAOYSA-N ethyl 2-amino-4-methyl-3-oxopentanoate;hydrochloride Chemical compound Cl.CCOC(=O)C(N)C(=O)C(C)C STXQYTGSIQCKFA-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 4
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- YPINLRNGSGGJJT-JXMROGBWSA-N (2e)-2-hydroxyimino-1-phenylpropan-1-one Chemical compound O\N=C(/C)C(=O)C1=CC=CC=C1 YPINLRNGSGGJJT-JXMROGBWSA-N 0.000 description 3
- YXXSKPPRENBIBF-GSLIJJQTSA-N (2s)-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@@H](CO[C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)C(O)=O)CC1=CC=C(C(F)(F)F)C=C1 YXXSKPPRENBIBF-GSLIJJQTSA-N 0.000 description 3
- FDBGURXQLIASAR-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-methyl-4-[(3-prop-2-enoxycyclohexyl)oxymethyl]-1,3-oxazole Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC1CCCC(OCC=C)C1 FDBGURXQLIASAR-UHFFFAOYSA-N 0.000 description 3
- MFDBEIHCSIVRCN-UXHICEINSA-N 2-ethyl-4-[(1r,3s)-3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxybut-2-enoic acid Chemical compound C1[C@H](OCC=C(CC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 MFDBEIHCSIVRCN-UXHICEINSA-N 0.000 description 3
- CMINROMQYDFVKZ-OHAXFNJZSA-N 2-ethyl-4-[(1r,3s)-3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxybutanoic acid Chemical compound C1[C@H](OCCC(CC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 CMINROMQYDFVKZ-OHAXFNJZSA-N 0.000 description 3
- WEWPHAAWLKAJKC-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-5-phenyl-1,3-oxazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=C(C=2C=CC=CC=2)O1 WEWPHAAWLKAJKC-UHFFFAOYSA-N 0.000 description 3
- XJKVVHCZKAADFP-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-5-methyl-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC(C)=C(CI)N=2)=C1 XJKVVHCZKAADFP-UHFFFAOYSA-N 0.000 description 3
- XWACKBMPGJMLFJ-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-(3-methylphenyl)-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 XWACKBMPGJMLFJ-UHFFFAOYSA-N 0.000 description 3
- ACMFBGDVEITOFZ-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 ACMFBGDVEITOFZ-UHFFFAOYSA-N 0.000 description 3
- OJSUKGKXAPQITL-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[3-(trifluoromethoxy)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=C(OC(F)(F)F)C=CC=2)=N1 OJSUKGKXAPQITL-UHFFFAOYSA-N 0.000 description 3
- SLYIGTWFTNDINH-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 SLYIGTWFTNDINH-UHFFFAOYSA-N 0.000 description 3
- XFLMZIVSUSURBJ-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-naphthalen-2-yl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=C3C=CC=CC3=CC=2)=N1 XFLMZIVSUSURBJ-UHFFFAOYSA-N 0.000 description 3
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- NIVGNNIVMXYXFG-UHFFFAOYSA-N 4-methyl-2-(4-methylphenyl)-3-oxido-5-phenyl-1,3-oxazol-3-ium Chemical compound [O-][N+]=1C(C)=C(C=2C=CC=CC=2)OC=1C1=CC=C(C)C=C1 NIVGNNIVMXYXFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OYAVEBCIIKQNLQ-VQTJNVASSA-N CC1=C(CO[C@@H](CCC2)C[C@@H]2OCOC(C2CC2)=O)N=C(C2=CC=CC(C)=C2)O1 Chemical compound CC1=C(CO[C@@H](CCC2)C[C@@H]2OCOC(C2CC2)=O)N=C(C2=CC=CC(C)=C2)O1 OYAVEBCIIKQNLQ-VQTJNVASSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 240000008886 Ceratonia siliqua Species 0.000 description 3
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 241000713333 Mouse mammary tumor virus Species 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- 229940126033 PPAR agonist Drugs 0.000 description 3
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 3
- 241000254064 Photinus pyralis Species 0.000 description 3
- 102000004257 Potassium Channel Human genes 0.000 description 3
- 108010052090 Renilla Luciferases Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- SMAOVIHJZYGLNT-UHFFFAOYSA-N ethyl 2-hydroxyimino-4-methyl-3-oxopentanoate Chemical compound CCOC(=O)C(=NO)C(=O)C(C)C SMAOVIHJZYGLNT-UHFFFAOYSA-N 0.000 description 3
- OCJKUQIPRNZDTK-UHFFFAOYSA-N ethyl 4,4,4-trifluoro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)C(F)(F)F OCJKUQIPRNZDTK-UHFFFAOYSA-N 0.000 description 3
- HDTDHYKMFULBIB-UHFFFAOYSA-N ethyl 4-methyl-2-[(4-methylbenzoyl)amino]-3-oxopentanoate Chemical compound CCOC(=O)C(C(=O)C(C)C)NC(=O)C1=CC=C(C)C=C1 HDTDHYKMFULBIB-UHFFFAOYSA-N 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 108020001213 potassium channel Proteins 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 229960002354 repaglinide Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- RCNVIAZJJPKRLG-UHFFFAOYSA-N tert-butyl-diphenyl-propoxysilane Chemical compound C=1C=CC=CC=1[Si](C(C)(C)C)(OCCC)C1=CC=CC=C1 RCNVIAZJJPKRLG-UHFFFAOYSA-N 0.000 description 3
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- AQKACENWDQZESU-PBOULFJWSA-N (2E,4E)-N-isobutyl-7-(3,4-methylenedioxyphenyl)-hepta-2,4-dienamide Chemical compound CC(C)CNC(=O)\C=C\C=C\CCC1=CC=C2OCOC2=C1 AQKACENWDQZESU-PBOULFJWSA-N 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- DFJTYRPOKMYJLU-YIKNKFAXSA-N (2r)-3-[(1r,3s)-3-[(5-methyl-2-naphthalen-2-yl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@H](CO[C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C2C=CC=CC2=CC=1)C(O)=O)CC1=CC=C(C(F)(F)F)C=C1 DFJTYRPOKMYJLU-YIKNKFAXSA-N 0.000 description 2
- YXXSKPPRENBIBF-BFLUCZKCSA-N (2r)-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@H](CO[C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)C(O)=O)CC1=CC=C(C(F)(F)F)C=C1 YXXSKPPRENBIBF-BFLUCZKCSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical group C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- KQDQZEZWWRPNQH-UHFFFAOYSA-N 1,3-diazabicyclo[2.2.2]octane Chemical compound C1CC2CCN1CN2 KQDQZEZWWRPNQH-UHFFFAOYSA-N 0.000 description 2
- BKZHSJNLPPAJKB-UHFFFAOYSA-N 1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea;hydrochloride Chemical compound Cl.C1=CN=C2C(NC(=O)NC3=CC=C4N=C(OC4=C3)C)=CC=NC2=C1 BKZHSJNLPPAJKB-UHFFFAOYSA-N 0.000 description 2
- IKSNDOVDVVPSMA-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CBr)C=C1 IKSNDOVDVVPSMA-UHFFFAOYSA-N 0.000 description 2
- PFFCLJDVINXVNR-RBUKOAKNSA-N 1-[[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxymethyl]cyclopropane-1-carboxylic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC1(C(O)=O)CC1 PFFCLJDVINXVNR-RBUKOAKNSA-N 0.000 description 2
- GIYZJSLQVOWCAR-UHFFFAOYSA-N 1-cyclohexyl-2-hydroxyiminopropan-1-one Chemical compound ON=C(C)C(=O)C1CCCCC1 GIYZJSLQVOWCAR-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- UEJHHKGNCWUBHD-UHFFFAOYSA-N 2-(4-fluorophenyl)-4-(iodomethyl)-5-methyl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 UEJHHKGNCWUBHD-UHFFFAOYSA-N 0.000 description 2
- ZDVRPKUWYQVVDX-UHFFFAOYSA-N 2-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC=C1C=O ZDVRPKUWYQVVDX-UHFFFAOYSA-N 0.000 description 2
- VNLHFRIFAMCIHY-UHFFFAOYSA-N 2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]acetaldehyde Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC1CCCC(CC=O)C1 VNLHFRIFAMCIHY-UHFFFAOYSA-N 0.000 description 2
- ISSPREHQQMHYMA-JCVDRHSJSA-N 2-ethoxy-3-[(1r,3s)-3-[(5-methyl-2-naphthalen-2-yl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C3C=CC=CC3=CC=2)=N1 ISSPREHQQMHYMA-JCVDRHSJSA-N 0.000 description 2
- MFFJJGUOJQGPTJ-ZOAFEQKISA-N 2-methoxy-3-[(1r,3s)-3-[(5-methyl-2-naphthalen-2-yl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C3C=CC=CC3=CC=2)=N1 MFFJJGUOJQGPTJ-ZOAFEQKISA-N 0.000 description 2
- NHOYTVJCIVUNRF-PZEDNMLSSA-N 2-methoxy-3-[(1r,3s)-3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC=CC=2)=N1 NHOYTVJCIVUNRF-PZEDNMLSSA-N 0.000 description 2
- UXFXUVAMGZQVTO-IVAAQHKWSA-N 2-methoxy-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 UXFXUVAMGZQVTO-IVAAQHKWSA-N 0.000 description 2
- SFHMXWCADKXPHU-FPHLKLNRSA-N 2-methoxy-3-[(1r,3s)-3-[[5-methyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 SFHMXWCADKXPHU-FPHLKLNRSA-N 0.000 description 2
- IFZLLUQRQZPTQW-GWFKTICUSA-N 2-methoxy-3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(OC(F)(F)F)C=CC=2)=N1 IFZLLUQRQZPTQW-GWFKTICUSA-N 0.000 description 2
- CBRFSDWTRQSMPP-PZEDNMLSSA-N 2-methoxy-3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C=CC=2)C(F)(F)F)=N1 CBRFSDWTRQSMPP-PZEDNMLSSA-N 0.000 description 2
- CHDMTTYVZFBRNZ-PZEDNMLSSA-N 2-methoxy-3-[(1r,3s)-3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 CHDMTTYVZFBRNZ-PZEDNMLSSA-N 0.000 description 2
- VQVRENONUXYEPP-GARIHTGFSA-N 3-[(1r,3s)-3-[[2-(2,4-dimethylphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methoxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC(C)=CC=2)C)=N1 VQVRENONUXYEPP-GARIHTGFSA-N 0.000 description 2
- NDGKYAYGLGCZBS-GARIHTGFSA-N 3-[(1r,3s)-3-[[2-(2,6-dimethylphenyl)-5-ethyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methoxypropanoic acid Chemical compound CCC=1OC(C=2C(=CC=CC=2C)C)=NC=1CO[C@H]1CCC[C@@H](OCC(OC)C(O)=O)C1 NDGKYAYGLGCZBS-GARIHTGFSA-N 0.000 description 2
- QYQCDGRJGUGQGP-IVAAQHKWSA-N 3-[(1r,3s)-3-[[2-(2,6-dimethylphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methoxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC=CC=2C)C)=N1 QYQCDGRJGUGQGP-IVAAQHKWSA-N 0.000 description 2
- GEGSPMOQMWOBPJ-RJKSWSIASA-N 3-[(1r,3s)-3-[[2-(3-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(OC)C=CC=2)=N1 GEGSPMOQMWOBPJ-RJKSWSIASA-N 0.000 description 2
- FQYFZVCWPANGTJ-RCCQNZRSSA-N 3-[(1r,3s)-3-[[5-ethyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C=CC(C)=CC=2)=N1 FQYFZVCWPANGTJ-RCCQNZRSSA-N 0.000 description 2
- WTKSOBVOIYJFMS-FQTTXOOSSA-N 3-[(1r,3s)-3-[[5-ethyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C=CC(=CC=2)C(C)C)=N1 WTKSOBVOIYJFMS-FQTTXOOSSA-N 0.000 description 2
- UIIGBNOUEQZOJI-VKWYCSODSA-N 3-[(1r,3s)-3-[[5-ethyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methoxypropanoic acid Chemical compound CCC=1OC(C=2C(=CC=CC=2)C(F)(F)F)=NC=1CO[C@H]1CCC[C@@H](OCC(OC)C(O)=O)C1 UIIGBNOUEQZOJI-VKWYCSODSA-N 0.000 description 2
- LAWKKFGROHFRNS-VIHOQOLSSA-N 3-[(1r,3s)-3-[[5-methyl-2-(2-naphthalen-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC=CC=2)C=2C=C3C=CC=CC3=CC=2)=N1 LAWKKFGROHFRNS-VIHOQOLSSA-N 0.000 description 2
- RNHRRUOQVQVUIT-RJKSWSIASA-N 3-[(1r,3s)-3-[[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(C)=CC=2)=N1 RNHRRUOQVQVUIT-RJKSWSIASA-N 0.000 description 2
- WVUWDMQFNWJJGO-JCVDRHSJSA-N 3-[(1r,3s)-3-[[5-methyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(=CC=2)C(C)C)=N1 WVUWDMQFNWJJGO-JCVDRHSJSA-N 0.000 description 2
- QXBYCFUHZXNZGG-NXRUOVBSSA-N 3-[(1r,3s)-3-[[5-methyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 QXBYCFUHZXNZGG-NXRUOVBSSA-N 0.000 description 2
- YTAGWZUNCHKJNH-KTVLMBSMSA-N 3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C=CC=2)C(F)(F)F)=N1 YTAGWZUNCHKJNH-KTVLMBSMSA-N 0.000 description 2
- UKSBRLCFLVAJNA-KTVLMBSMSA-N 3-[(1r,3s)-3-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(OC(F)(F)F)=CC=2)=N1 UKSBRLCFLVAJNA-KTVLMBSMSA-N 0.000 description 2
- RRSMWVVGYPRIGB-KTVLMBSMSA-N 3-[(1r,3s)-3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 RRSMWVVGYPRIGB-KTVLMBSMSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- SOINZDZUVFPFLV-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-(5-methylfuran-2-yl)-1,3-oxazole Chemical compound O1C(C)=CC=C1C1=NC(CI)=C(C)O1 SOINZDZUVFPFLV-UHFFFAOYSA-N 0.000 description 2
- RIPPLGSFZLWCCG-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC(OC(F)(F)F)=CC=2)=N1 RIPPLGSFZLWCCG-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 2
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 description 2
- HSJYZRUAFNGACR-UHFFFAOYSA-N 5-ethyl-4-(iodomethyl)-2-[2-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 HSJYZRUAFNGACR-UHFFFAOYSA-N 0.000 description 2
- OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 description 2
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000003810 Jones reagent Substances 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 206010023330 Keloid scar Diseases 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 102000005630 Urocortins Human genes 0.000 description 2
- 108010059705 Urocortins Proteins 0.000 description 2
- HQTZHHDTBSHTDM-CVEARBPZSA-N [(1s,3r)-3-prop-2-enoxycyclohexyl]oxymethylbenzene Chemical compound C1[C@H](OCC=C)CCC[C@@H]1OCC1=CC=CC=C1 HQTZHHDTBSHTDM-CVEARBPZSA-N 0.000 description 2
- QJHAWRGKDNXWIY-UHFFFAOYSA-N [2-(4-methylphenyl)-5-propan-2-yl-1,3-oxazol-4-yl]methanol Chemical compound OCC1=C(C(C)C)OC(C=2C=CC(C)=CC=2)=N1 QJHAWRGKDNXWIY-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 150000001351 alkyl iodides Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- WTWBUQJHJGUZCY-UHFFFAOYSA-N cuminaldehyde Chemical compound CC(C)C1=CC=C(C=O)C=C1 WTWBUQJHJGUZCY-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960004597 dexfenfluramine Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- XWKOSAYDZJXYQO-UHFFFAOYSA-N ethyl 2-(4-methylphenyl)-5-propan-2-yl-1,3-oxazole-4-carboxylate Chemical compound O1C(C(C)C)=C(C(=O)OCC)N=C1C1=CC=C(C)C=C1 XWKOSAYDZJXYQO-UHFFFAOYSA-N 0.000 description 2
- MTCMFVTVXAOHNQ-UHFFFAOYSA-N ethyl 2-(bromomethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)CBr MTCMFVTVXAOHNQ-UHFFFAOYSA-N 0.000 description 2
- MVHIIPHBVXIUCL-YADHBBJMSA-N ethyl 2-ethyl-4-[(1r,3s)-3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxybut-2-enoate Chemical compound C1[C@H](OCC=C(CC)C(=O)OCC)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 MVHIIPHBVXIUCL-YADHBBJMSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 102000054223 human PPARA Human genes 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940060975 lantus Drugs 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229950004994 meglitinide Drugs 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000004665 trialkylsilyl group Chemical group 0.000 description 2
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000000777 urocortin Substances 0.000 description 2
- MBMQEIFVQACCCH-QBODLPLBSA-N zearalenone Chemical compound O=C1O[C@@H](C)CCCC(=O)CCC\C=C\C2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-QBODLPLBSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical group CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- QKCWUSGSHMIBCN-SQJMNOBHSA-N (1r,3s)-3-(trityloxymethyl)cyclohexan-1-ol Chemical compound C1[C@H](O)CCC[C@@H]1COC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 QKCWUSGSHMIBCN-SQJMNOBHSA-N 0.000 description 1
- RFCYVWGCOXVSBD-OLZOCXBDSA-N (1r,3s)-3-phenylmethoxycyclohexan-1-ol Chemical compound C1[C@H](O)CCC[C@@H]1OCC1=CC=CC=C1 RFCYVWGCOXVSBD-OLZOCXBDSA-N 0.000 description 1
- SSJXIUAHEKJCMH-WDSKDSINSA-N (1s,2s)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@@H]1N SSJXIUAHEKJCMH-WDSKDSINSA-N 0.000 description 1
- HXAVIGJRKGAOAC-GEWUYGHSSA-N (2r)-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxymethyl]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@H](CO[C@@H]1CCC[C@@H](C1)COCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)C(O)=O)CC1=CC=C(C(F)(F)F)C=C1 HXAVIGJRKGAOAC-GEWUYGHSSA-N 0.000 description 1
- MBFPZJPLBYFTFI-ZRRKCSAHSA-N (2r)-3-[(1r,3s)-3-[[5-methyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound C1=CC(C(C)C)=CC=C1C1=NC(CO[C@@H]2C[C@@H](CCC2)OC[C@@H](OCC=2C=CC(=CC=2)C(F)(F)F)C(O)=O)=C(C)O1 MBFPZJPLBYFTFI-ZRRKCSAHSA-N 0.000 description 1
- ABCQNYILLLXKLF-JBRSBNLGSA-N (2r)-3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@H](CO[C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C=CC=1)C(F)(F)F)C(O)=O)CC1=CC=C(C(F)(F)F)C=C1 ABCQNYILLLXKLF-JBRSBNLGSA-N 0.000 description 1
- HXAVIGJRKGAOAC-RWUBSVTLSA-N (2s)-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxymethyl]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@@H](CO[C@@H]1CCC[C@@H](C1)COCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)C(O)=O)CC1=CC=C(C(F)(F)F)C=C1 HXAVIGJRKGAOAC-RWUBSVTLSA-N 0.000 description 1
- ALSCEGDXFJIYES-YFKPBYRVSA-N (2s)-pyrrolidine-2-carbonitrile Chemical compound N#C[C@@H]1CCCN1 ALSCEGDXFJIYES-YFKPBYRVSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- OMXRTIUYSHDUTH-UHFFFAOYSA-N 1-(3-ethyl-1-benzofuran-7-yl)piperazine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC=C2C(CC)=COC2=C1N1CCNCC1 OMXRTIUYSHDUTH-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- FXFUBSNEYXTGNP-XQFMJXHWSA-N 1-[tert-butyl(dimethyl)silyl]oxy-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropan-2-ol Chemical compound CC=1OC(C=2C=C(C)C=CC=2)=NC=1CO[C@H]1CCC[C@@H](OCC(O)CO[Si](C)(C)C(C)(C)C)C1 FXFUBSNEYXTGNP-XQFMJXHWSA-N 0.000 description 1
- DEFNUDNHTUZJAL-UHFFFAOYSA-N 1-bromo-2-methylprop-1-ene Chemical compound CC(C)=CBr DEFNUDNHTUZJAL-UHFFFAOYSA-N 0.000 description 1
- IOCSSHWOWKBYMI-BCQQZXIPSA-N 1-bromo-3-(trifluoromethyl)benzene;2-[[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxymethyl]-3-[3-(trifluoromethyl)phenyl]propanoic acid Chemical compound FC(F)(F)C1=CC=CC(Br)=C1.O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)CC1=CC=CC(C(F)(F)F)=C1 IOCSSHWOWKBYMI-BCQQZXIPSA-N 0.000 description 1
- IZWIMRSEBZHUAD-UHFFFAOYSA-N 1-prop-2-ynoxypropan-1-ol Chemical compound C(C#C)OC(CC)O IZWIMRSEBZHUAD-UHFFFAOYSA-N 0.000 description 1
- GISVICWQYMUPJF-UHFFFAOYSA-N 2,4-Dimethylbenzaldehyde Chemical compound CC1=CC=C(C=O)C(C)=C1 GISVICWQYMUPJF-UHFFFAOYSA-N 0.000 description 1
- QOJQBWSZHCKOLL-UHFFFAOYSA-N 2,6-dimethylbenzaldehyde Chemical compound CC1=CC=CC(C)=C1C=O QOJQBWSZHCKOLL-UHFFFAOYSA-N 0.000 description 1
- ARNCUSIEBKDVTJ-UHFFFAOYSA-N 2-(2,6-dimethylphenyl)-4-(iodomethyl)-5-methyl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C(=CC=CC=2C)C)=N1 ARNCUSIEBKDVTJ-UHFFFAOYSA-N 0.000 description 1
- ANFNOYNIAFXHFF-RJKSWSIASA-N 2-(2-methylpropoxy)-3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC(C)C)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C=CC=2)C(F)(F)F)=N1 ANFNOYNIAFXHFF-RJKSWSIASA-N 0.000 description 1
- HAWSTCYOCUMUIJ-UHFFFAOYSA-N 2-(4-methylphenyl)-5-(trifluoromethyl)-1,3-oxazole Chemical compound CC1=CC=C(C=C1)C=1OC(=CN=1)C(F)(F)F HAWSTCYOCUMUIJ-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- CKKXBBNLSRIAOY-VEPNZUSMSA-N 2-[(2,5-dimethylphenyl)methoxy]-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC(C)=CC=C1C CKKXBBNLSRIAOY-VEPNZUSMSA-N 0.000 description 1
- ARGSBCMRQQCCAY-QDSWCARHSA-N 2-[(3-methoxyphenyl)methoxy]-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound COC1=CC=CC(COC(CO[C@H]2C[C@H](CCC2)OCC2=C(OC(=N2)C=2C=C(C)C=CC=2)C)C(O)=O)=C1 ARGSBCMRQQCCAY-QDSWCARHSA-N 0.000 description 1
- WAYZWXLEBGEFKA-ZDCXKQOISA-N 2-[(4-tert-butylphenyl)methoxy]-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=C(C(C)(C)C)C=C1 WAYZWXLEBGEFKA-ZDCXKQOISA-N 0.000 description 1
- WQJIOTWPJDPPHW-RCCQNZRSSA-N 2-[(5-chlorothiophen-2-yl)methoxy]-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=C(Cl)S1 WQJIOTWPJDPPHW-RCCQNZRSSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- DKDSZOOZDBVUAH-UHFFFAOYSA-N 2-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxyethyl]pentanoic acid Chemical compound C1C(OCCC(CCC)C(O)=O)CCCC1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 DKDSZOOZDBVUAH-UHFFFAOYSA-N 0.000 description 1
- UJGBTZUTZSMGCO-UHFFFAOYSA-N 2-[2-[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-1,3-thiazol-2-yl]carbamoyl]-5,7-dimethylindol-1-yl]acetic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(Cl)C(OC)=CC(C2=C(SC(NC(=O)C=3N(C4=C(C)C=C(C)C=C4C=3)CC(O)=O)=N2)CCC2CCCCC2)=C1OC UJGBTZUTZSMGCO-UHFFFAOYSA-N 0.000 description 1
- FAUGURYODQJLOV-UHFFFAOYSA-N 2-[4-(iodomethyl)-5-methylnaphthalen-2-yl]-1,3-oxazole Chemical compound C=1C(CI)=C2C(C)=CC=CC2=CC=1C1=NC=CO1 FAUGURYODQJLOV-UHFFFAOYSA-N 0.000 description 1
- SDHLTWJVIIREOF-GOGAEGRDSA-N 2-[[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxymethyl]-3-[3-(trifluoromethyl)phenyl]propanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)CC1=CC=CC(C(F)(F)F)=C1 SDHLTWJVIIREOF-GOGAEGRDSA-N 0.000 description 1
- ODPWGDNCQVMMNT-ZOAFEQKISA-N 2-but-2-ynoxy-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC#CC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 ODPWGDNCQVMMNT-ZOAFEQKISA-N 0.000 description 1
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 description 1
- MQTKXCOGYOYAMW-UHFFFAOYSA-N 2-chloro-5-(chloromethyl)thiophene Chemical compound ClCC1=CC=C(Cl)S1 MQTKXCOGYOYAMW-UHFFFAOYSA-N 0.000 description 1
- WOAKKLLAVUWBDI-IVAAQHKWSA-N 2-ethoxy-3-[(1r,3s)-3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC=CC=2)=N1 WOAKKLLAVUWBDI-IVAAQHKWSA-N 0.000 description 1
- PESRNTYCYSEXIL-KTVLMBSMSA-N 2-ethoxy-3-[(1r,3s)-3-[[2-(3-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(OC)C=CC=2)=N1 PESRNTYCYSEXIL-KTVLMBSMSA-N 0.000 description 1
- YDFDBYWGPSSEBO-WQFBUZOZSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-ethyl-2-(2-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C(=CC=CC=2)C)=N1 YDFDBYWGPSSEBO-WQFBUZOZSA-N 0.000 description 1
- WATQRZILZRLBLA-LDJQHZOJSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-ethyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C=CC(=CC=2)C(C)C)=N1 WATQRZILZRLBLA-LDJQHZOJSA-N 0.000 description 1
- OUCXLLHJTMFYRI-PTHSTZKBSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-ethyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 OUCXLLHJTMFYRI-PTHSTZKBSA-N 0.000 description 1
- WKJHFRSWZKSOMW-KTVLMBSMSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 WKJHFRSWZKSOMW-KTVLMBSMSA-N 0.000 description 1
- SJOPWTFCLAXZPR-KTVLMBSMSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(C)=CC=2)=N1 SJOPWTFCLAXZPR-KTVLMBSMSA-N 0.000 description 1
- ULNKGCWASNUVLP-ZOAFEQKISA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(=CC=2)C(C)C)=N1 ULNKGCWASNUVLP-ZOAFEQKISA-N 0.000 description 1
- JQMGVQWWVXUCCO-QRFGBVCESA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 JQMGVQWWVXUCCO-QRFGBVCESA-N 0.000 description 1
- OXSWNMGVILHANM-QJNHQHDKSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(OC(F)(F)F)C=CC=2)=N1 OXSWNMGVILHANM-QJNHQHDKSA-N 0.000 description 1
- JNORNIVLLYTVNH-IVAAQHKWSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C=CC=2)C(F)(F)F)=N1 JNORNIVLLYTVNH-IVAAQHKWSA-N 0.000 description 1
- URGNWGPYJKRMNR-IVAAQHKWSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(OC(F)(F)F)=CC=2)=N1 URGNWGPYJKRMNR-IVAAQHKWSA-N 0.000 description 1
- XLMLIXHOFLDWEY-IVAAQHKWSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 XLMLIXHOFLDWEY-IVAAQHKWSA-N 0.000 description 1
- IBIMXAAZWOQNDX-UHFFFAOYSA-N 2-ethyl-3-(iodomethyl)-5-(4-methylphenyl)-1h-pyrrole Chemical compound ICC1=C(CC)NC(C=2C=CC(C)=CC=2)=C1 IBIMXAAZWOQNDX-UHFFFAOYSA-N 0.000 description 1
- ZYQGJKOCXWIBCS-IVAAQHKWSA-N 2-methoxy-3-[(1r,3s)-3-[[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(C)=CC=2)=N1 ZYQGJKOCXWIBCS-IVAAQHKWSA-N 0.000 description 1
- ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 2-methyl-1,3-oxazole Chemical compound CC1=NC=CO1 ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 0.000 description 1
- YCOXJFAUNLRWPU-UHFFFAOYSA-N 2-methyl-n,n-dipropyl-9-(2,4,6-trimethylphenyl)pyrimido[4,5-b]indol-4-amine Chemical compound C12=CC=CC=C2C=2C(N(CCC)CCC)=NC(C)=NC=2N1C1=C(C)C=C(C)C=C1C YCOXJFAUNLRWPU-UHFFFAOYSA-N 0.000 description 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 description 1
- LCRCBXLHWTVPEQ-UHFFFAOYSA-N 2-phenylbenzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CC=CC=C1 LCRCBXLHWTVPEQ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
- FQEVHRCPXFKJHF-UHFFFAOYSA-N 3-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=CC(C=O)=C1 FQEVHRCPXFKJHF-UHFFFAOYSA-N 0.000 description 1
- RUJYJCANMOTJMO-UHFFFAOYSA-N 3-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC(C(Cl)=O)=C1 RUJYJCANMOTJMO-UHFFFAOYSA-N 0.000 description 1
- NDBUCZOFHAHPIR-KTVLMBSMSA-N 3-[(1r,3s)-3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC=CC=2)=N1 NDBUCZOFHAHPIR-KTVLMBSMSA-N 0.000 description 1
- NOIUCUFRAOHIBH-HXIJRHRVSA-N 3-[(1r,3s)-3-[[2-(2,4-dimethylphenyl)-5-ethyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-ethoxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C(=CC(C)=CC=2)C)=N1 NOIUCUFRAOHIBH-HXIJRHRVSA-N 0.000 description 1
- AUDSTWRPKXPLOV-ZKTCVHQMSA-N 3-[(1r,3s)-3-[[2-(2,4-dimethylphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-ethoxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC(C)=CC=2)C)=N1 AUDSTWRPKXPLOV-ZKTCVHQMSA-N 0.000 description 1
- GVQGZAJWXFQBRI-RCCQNZRSSA-N 3-[(1r,3s)-3-[[2-(2,6-dimethylphenyl)-5-ethyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C(=CC=CC=2C)C)=N1 GVQGZAJWXFQBRI-RCCQNZRSSA-N 0.000 description 1
- KXFCNFIFTNZBHX-ZOAFEQKISA-N 3-[(1r,3s)-3-[[2-(3-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-(2-methylpropoxy)propanoic acid Chemical compound COC1=CC=CC(C=2OC(C)=C(CO[C@@H]3C[C@@H](CCC3)OCC(OCC(C)C)C(O)=O)N=2)=C1 KXFCNFIFTNZBHX-ZOAFEQKISA-N 0.000 description 1
- KWGGYADYRRWBED-GARIHTGFSA-N 3-[(1r,3s)-3-[[5-ethyl-2-(3-methoxyphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methoxypropanoic acid Chemical compound CCC=1OC(C=2C=C(OC)C=CC=2)=NC=1CO[C@H]1CCC[C@@H](OCC(OC)C(O)=O)C1 KWGGYADYRRWBED-GARIHTGFSA-N 0.000 description 1
- UKFJLKWJFZFIAC-GARIHTGFSA-N 3-[(1r,3s)-3-[[5-ethyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methoxypropanoic acid Chemical compound CCC=1OC(C=2C=CC(C)=CC=2)=NC=1CO[C@H]1CCC[C@@H](OCC(OC)C(O)=O)C1 UKFJLKWJFZFIAC-GARIHTGFSA-N 0.000 description 1
- WOOTXPMIZUFJRQ-NCHORFDRSA-N 3-[(1r,3s)-3-[[5-ethyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 WOOTXPMIZUFJRQ-NCHORFDRSA-N 0.000 description 1
- ITDRKCOOVMPGGY-ZOAFEQKISA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-(2-methylprop-2-enoxy)propanoic acid Chemical compound C1[C@H](OCC(OCC(=C)C)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 ITDRKCOOVMPGGY-ZOAFEQKISA-N 0.000 description 1
- TTXMWZQHPXTCCU-VEPNZUSMSA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-(3-phenylprop-2-enoxy)propanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC=CC1=CC=CC=C1 TTXMWZQHPXTCCU-VEPNZUSMSA-N 0.000 description 1
- NTSSMZLSKXODID-QDSWCARHSA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[(4-methylphenyl)methoxy]propanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=C(C)C=C1 NTSSMZLSKXODID-QDSWCARHSA-N 0.000 description 1
- GPUNDHQYVUIIKS-MXKXXCEUSA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[2-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=CC=C1C(F)(F)F GPUNDHQYVUIIKS-MXKXXCEUSA-N 0.000 description 1
- UGJIQXNPMSEYSB-GPTJOGTASA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[3-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=CC(C(F)(F)F)=C1 UGJIQXNPMSEYSB-GPTJOGTASA-N 0.000 description 1
- RSMWJHBZGDSYBU-JCVDRHSJSA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-pent-2-ynoxypropanoic acid Chemical compound C1[C@H](OCC(OCC#CCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 RSMWJHBZGDSYBU-JCVDRHSJSA-N 0.000 description 1
- DRUJFZBMHLGGOZ-GPTJOGTASA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-phenylmethoxypropanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=CC=C1 DRUJFZBMHLGGOZ-GPTJOGTASA-N 0.000 description 1
- JSSLXQVFFDMJAQ-RJKSWSIASA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-prop-2-enoxypropanoic acid Chemical compound CC=1OC(C=2C=C(C)C=CC=2)=NC=1CO[C@H]1CCC[C@@H](OCC(OCC=C)C(O)=O)C1 JSSLXQVFFDMJAQ-RJKSWSIASA-N 0.000 description 1
- XBAHJRILVGQVRV-RJKSWSIASA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-prop-2-ynoxypropanoic acid Chemical compound CC=1OC(C=2C=C(C)C=CC=2)=NC=1CO[C@H]1CCC[C@@H](OCC(OCC#C)C(O)=O)C1 XBAHJRILVGQVRV-RJKSWSIASA-N 0.000 description 1
- JTNVAZIMNQBJFU-RJKSWSIASA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 JTNVAZIMNQBJFU-RJKSWSIASA-N 0.000 description 1
- HDCGYCSLBSXTPX-ZOAFEQKISA-N 3-[(1r,3s)-3-[[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-(2-methylpropoxy)propanoic acid Chemical compound C1[C@H](OCC(OCC(C)C)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(C)=CC=2)=N1 HDCGYCSLBSXTPX-ZOAFEQKISA-N 0.000 description 1
- UCMCZJXIDLEOMX-YGHPRADISA-N 3-[(1r,3s)-3-[[5-methyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-(2-methylpropoxy)propanoic acid Chemical compound C1[C@H](OCC(OCC(C)C)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(=CC=2)C(C)C)=N1 UCMCZJXIDLEOMX-YGHPRADISA-N 0.000 description 1
- CURXXYXICBBGDO-GARIHTGFSA-N 3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(OC(F)(F)F)C=CC=2)=N1 CURXXYXICBBGDO-GARIHTGFSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- TWJQZBXURHWBPV-UHFFFAOYSA-N 3-cyclohexyl-1-(4,4-dimethyl-6,7-dihydro-1h-imidazo[4,5-c]pyridin-5-yl)propan-1-one;oxalic acid Chemical compound OC(=O)C(O)=O.C1CC=2NC=NC=2C(C)(C)N1C(=O)CCC1CCCCC1 TWJQZBXURHWBPV-UHFFFAOYSA-N 0.000 description 1
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
- VCTKYTBWZTZPHF-UHFFFAOYSA-N 4-(chloromethyl)-5-methyl-2-phenyl-1,3-oxazole Chemical compound ClCC1=C(C)OC(C=2C=CC=CC=2)=N1 VCTKYTBWZTZPHF-UHFFFAOYSA-N 0.000 description 1
- DOSVJMCCPCFNCO-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC=C(CI)N=2)=C1 DOSVJMCCPCFNCO-UHFFFAOYSA-N 0.000 description 1
- OKHGLMQXLUEZMI-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-5-phenyl-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC(=C(CI)N=2)C=2C=CC=CC=2)=C1 OKHGLMQXLUEZMI-UHFFFAOYSA-N 0.000 description 1
- UUOZIINDOMFDBE-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-5-propan-2-yl-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC(=C(CI)N=2)C(C)C)=C1 UUOZIINDOMFDBE-UHFFFAOYSA-N 0.000 description 1
- CUPROPFTDOKVRM-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methoxyphenyl)-5-methyl-1,3-oxazole Chemical compound C1=CC(OC)=CC=C1C1=NC(CI)=C(C)O1 CUPROPFTDOKVRM-UHFFFAOYSA-N 0.000 description 1
- VBEYNUQRWAKFMV-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methylphenyl)-1,3-oxazole Chemical compound C1=CC(C)=CC=C1C1=NC(CI)=CO1 VBEYNUQRWAKFMV-UHFFFAOYSA-N 0.000 description 1
- OHVWIGRETNBHOI-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-propan-2-ylphenyl)-1,3-oxazole Chemical compound C1=CC(C(C)C)=CC=C1C1=NC(CI)=CO1 OHVWIGRETNBHOI-UHFFFAOYSA-N 0.000 description 1
- XHVLHNBJYTXNHA-UHFFFAOYSA-N 4-(iodomethyl)-2-[2-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound FC(F)(F)C1=CC=CC=C1C1=NC(CI)=CO1 XHVLHNBJYTXNHA-UHFFFAOYSA-N 0.000 description 1
- MRSKWSKTUZNPPK-UHFFFAOYSA-N 4-(iodomethyl)-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazole Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=NC(CI)=CO1 MRSKWSKTUZNPPK-UHFFFAOYSA-N 0.000 description 1
- NYFYEHIGJXMWHU-UHFFFAOYSA-N 4-(iodomethyl)-2-[4-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=NC(CI)=CO1 NYFYEHIGJXMWHU-UHFFFAOYSA-N 0.000 description 1
- AUXXYEOGNXWTJT-UHFFFAOYSA-N 4-(iodomethyl)-2-phenyl-1,3-oxazole Chemical compound ICC1=COC(C=2C=CC=CC=2)=N1 AUXXYEOGNXWTJT-UHFFFAOYSA-N 0.000 description 1
- URSQQDZMMODUMK-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-thiophen-2-yl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2SC=CC=2)=N1 URSQQDZMMODUMK-UHFFFAOYSA-N 0.000 description 1
- VSJDFQODQBDEHI-UHFFFAOYSA-N 4-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxybutanoic acid Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC1CCCC(OCCCC(O)=O)C1 VSJDFQODQBDEHI-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- KBIHBGYYYFRDEA-UHFFFAOYSA-N 5-ethyl-4-(iodomethyl)-2-(4-methylphenyl)-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C=CC(C)=CC=2)=N1 KBIHBGYYYFRDEA-UHFFFAOYSA-N 0.000 description 1
- PBFCTVPSJFFZSU-UHFFFAOYSA-N 5-ethyl-4-(iodomethyl)-2-(4-propan-2-ylphenyl)-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C=CC(=CC=2)C(C)C)=N1 PBFCTVPSJFFZSU-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102000004146 ATP citrate synthases Human genes 0.000 description 1
- 108090000662 ATP citrate synthases Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- XUQUNOFNOLPWSH-LTHQHPTJSA-N C/C=C(\c1ccccc1)/O/C(/c1ccc(C)cc1)=[NH+]/[O-] Chemical compound C/C=C(\c1ccccc1)/O/C(/c1ccc(C)cc1)=[NH+]/[O-] XUQUNOFNOLPWSH-LTHQHPTJSA-N 0.000 description 1
- YIXRGAIYTFCQLI-PVHODMMVSA-N CC(C)(C)[Si+](C)(C)OC[C@H](CO[C@H](CCC1)C[C@H]1OCc1c(C)[o]c(-c2cc(C)ccc2)n1)OCC#C Chemical compound CC(C)(C)[Si+](C)(C)OC[C@H](CO[C@H](CCC1)C[C@H]1OCc1c(C)[o]c(-c2cc(C)ccc2)n1)OCC#C YIXRGAIYTFCQLI-PVHODMMVSA-N 0.000 description 1
- RCLPUYNZEVAQHB-UOCPRXARSA-N CC(C)(C)[SiH-](c1ccccc1)(c1ccccc1)OCC(CO[C@H](CCC1)C[C@H]1OCc1ccccc1)OC Chemical compound CC(C)(C)[SiH-](c1ccccc1)(c1ccccc1)OCC(CO[C@H](CCC1)C[C@H]1OCc1ccccc1)OC RCLPUYNZEVAQHB-UOCPRXARSA-N 0.000 description 1
- KAHCLIOGUZERBY-ZVTBYLAHSA-N CC(C)(C)[Si](c1ccccc1)(c1ccccc1)OCC(CO[C@H](CCC1)C[C@H]1O)OC Chemical compound CC(C)(C)[Si](c1ccccc1)(c1ccccc1)OCC(CO[C@H](CCC1)C[C@H]1O)OC KAHCLIOGUZERBY-ZVTBYLAHSA-N 0.000 description 1
- QDMGUQRVUDTGDF-UHFFFAOYSA-N CC(CCC1)C/C1=[O]/Cc1c(C)[o]c(-c2cc(C)ccc2)n1 Chemical compound CC(CCC1)C/C1=[O]/Cc1c(C)[o]c(-c2cc(C)ccc2)n1 QDMGUQRVUDTGDF-UHFFFAOYSA-N 0.000 description 1
- MGLUFTIURPYNFJ-UHFFFAOYSA-N CC1=CC=C(C=C1)C2=CC(=C(N2)C3=CC=CC=C3)CCl Chemical compound CC1=CC=C(C=C1)C2=CC(=C(N2)C3=CC=CC=C3)CCl MGLUFTIURPYNFJ-UHFFFAOYSA-N 0.000 description 1
- RZDNNBPIXCXDEQ-ITAUSPCMSA-N CCCOC(CO)CO[C@H](CCC1)CC1OCc1c(C)[o]c(-c2cccc(C)c2)n1 Chemical compound CCCOC(CO)CO[C@H](CCC1)CC1OCc1c(C)[o]c(-c2cccc(C)c2)n1 RZDNNBPIXCXDEQ-ITAUSPCMSA-N 0.000 description 1
- PQVLCIAMIQFTCJ-UHFFFAOYSA-N CCCOC(COCC(CCC1)CC1OCc1c(CC)[o]c(-c2ccc(C(C)C)cc2)n1)C(O)=O Chemical compound CCCOC(COCC(CCC1)CC1OCc1c(CC)[o]c(-c2ccc(C(C)C)cc2)n1)C(O)=O PQVLCIAMIQFTCJ-UHFFFAOYSA-N 0.000 description 1
- MMGCWVVBEJSQHR-OADZCNSWSA-N CCCOC(CO[C@H](CCC1)CC1O)CO[Si+](C(C)(C)C)(c1ccccc1)c1ccccc1 Chemical compound CCCOC(CO[C@H](CCC1)CC1O)CO[Si+](C(C)(C)C)(c1ccccc1)c1ccccc1 MMGCWVVBEJSQHR-OADZCNSWSA-N 0.000 description 1
- YDPWWNONDZJGEV-XAGPSQNTSA-N CCOC(CO[C@H](CCC1)C[C@H]1O)CO[Si+](C(C)(C)C)(c1ccccc1)c1ccccc1 Chemical compound CCOC(CO[C@H](CCC1)C[C@H]1O)CO[Si+](C(C)(C)C)(c1ccccc1)c1ccccc1 YDPWWNONDZJGEV-XAGPSQNTSA-N 0.000 description 1
- NGBNUEIXIRLOQR-UHFFFAOYSA-N CCc1c(CI)nc(-c2c(C)cccc2C)[o]1 Chemical compound CCc1c(CI)nc(-c2c(C)cccc2C)[o]1 NGBNUEIXIRLOQR-UHFFFAOYSA-N 0.000 description 1
- NDGKYAYGLGCZBS-UHFFFAOYSA-N CCc1c(COC(CCC2)CC2OCC(C(O)=O)OC)nc(-c2c(C)cccc2C)[o]1 Chemical compound CCc1c(COC(CCC2)CC2OCC(C(O)=O)OC)nc(-c2c(C)cccc2C)[o]1 NDGKYAYGLGCZBS-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- LJKFLYGWGNOMFS-UHFFFAOYSA-N Cc1c(COC(CCC2)CC2OCC(CO)OCC#C)nc(-c2cccc(C)c2)[o]1 Chemical compound Cc1c(COC(CCC2)CC2OCC(CO)OCC#C)nc(-c2cccc(C)c2)[o]1 LJKFLYGWGNOMFS-UHFFFAOYSA-N 0.000 description 1
- KVNHEYRCTGTZOI-UHFFFAOYSA-N Cc1c(COC(CCC2)CC2OCC=C)nc(-c2cc(C)ccc2)[o]1 Chemical compound Cc1c(COC(CCC2)CC2OCC=C)nc(-c2cc(C)ccc2)[o]1 KVNHEYRCTGTZOI-UHFFFAOYSA-N 0.000 description 1
- YIGOQTBYVANVNT-UHFFFAOYSA-N Cc1c(COC2CC(COCC(C(O)=O)OCC#CC)CCC2)nc(-c2cccc(C)c2)[o]1 Chemical compound Cc1c(COC2CC(COCC(C(O)=O)OCC#CC)CCC2)nc(-c2cccc(C)c2)[o]1 YIGOQTBYVANVNT-UHFFFAOYSA-N 0.000 description 1
- FEPPYIYGXFNXOH-MDWZMJQESA-N Cc1c(COCC(CCC2)CC2OCC(C(O)=O)OC/C=C/c2ccccc2)nc(-c2cccc(C)c2)[o]1 Chemical compound Cc1c(COCC(CCC2)CC2OCC(C(O)=O)OC/C=C/c2ccccc2)nc(-c2cccc(C)c2)[o]1 FEPPYIYGXFNXOH-MDWZMJQESA-N 0.000 description 1
- HXAVIGJRKGAOAC-UHFFFAOYSA-N Cc1c(COCC(CCC2)CC2OCC(C(O)=O)OCc2ccc(C(F)(F)F)cc2)nc(-c2cc(C)ccc2)[o]1 Chemical compound Cc1c(COCC(CCC2)CC2OCC(C(O)=O)OCc2ccc(C(F)(F)F)cc2)nc(-c2cc(C)ccc2)[o]1 HXAVIGJRKGAOAC-UHFFFAOYSA-N 0.000 description 1
- PTQXRQMTWKVSOY-CVEARBPZSA-N Cc1c(CO[C@@H](CCC2)C[C@@H]2O)nc(-c2cc(C)ccc2)[o]1 Chemical compound Cc1c(CO[C@@H](CCC2)C[C@@H]2O)nc(-c2cc(C)ccc2)[o]1 PTQXRQMTWKVSOY-CVEARBPZSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 208000032541 Epidermal naevus Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102000019432 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 description 1
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 229940122014 Lyase inhibitor Drugs 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229940124757 MC-4 agonist Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- UULIGRNKXHCLQN-UHFFFAOYSA-N N-[[4-[[(4-amino-2-quinazolinyl)amino]methyl]cyclohexyl]methyl]-1-naphthalenesulfonamide Chemical compound C1=CC=C2C(N)=NC(NCC3CCC(CNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)CC3)=NC2=C1 UULIGRNKXHCLQN-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- IKGIOPLEUHSJBC-UHFFFAOYSA-N OCC(COC(CCC1)CC1OCc1ccccc1)O Chemical compound OCC(COC(CCC1)CC1OCc1ccccc1)O IKGIOPLEUHSJBC-UHFFFAOYSA-N 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229940123495 Squalene synthetase inhibitor Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 102000008200 Uncoupling Protein 3 Human genes 0.000 description 1
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 1
- 229940112930 apidra Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- BMWITAUNXBHIPO-OZZZDHQUSA-N benzenesulfonic acid;(2s,4s)-4-fluoro-1-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound OS(=O)(=O)C1=CC=CC=C1.OCC(C)(C)NCC(=O)N1C[C@@H](F)C[C@H]1C#N BMWITAUNXBHIPO-OZZZDHQUSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- AITJZYHNAKUCFP-UHFFFAOYSA-N diethyl 4-(4-fluorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=C(F)C=C1 AITJZYHNAKUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000005906 dihydroxylation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- GYUCVQSNZFRDRL-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylbutanoate Chemical compound CCOC(=O)C(CC)P(=O)(OCC)OCC GYUCVQSNZFRDRL-UHFFFAOYSA-N 0.000 description 1
- BUPVIVDUPRDDFI-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylpentanoate Chemical compound CCOC(=O)C(CCC)P(=O)(OCC)OCC BUPVIVDUPRDDFI-UHFFFAOYSA-N 0.000 description 1
- XCLDSQRVMMXWMS-UHFFFAOYSA-N ethyl 4-methyl-3-oxopentanoate Chemical compound CCOC(=O)CC(=O)C(C)C XCLDSQRVMMXWMS-UHFFFAOYSA-N 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 108700039926 insulin glulisine Proteins 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002697 lyase inhibitor Substances 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- LXEDKSZTPGCEPU-UHFFFAOYSA-N n-[2-(3a-benzyl-2-methyl-3-oxo-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]-1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxamide Chemical compound O=C1N(C)N=C2CCN(C(=O)C(NC(=O)C3C(C4=CC=CC=C4CC3)N)C=3C=CC(Cl)=CC=3)CC21CC1=CC=CC=C1 LXEDKSZTPGCEPU-UHFFFAOYSA-N 0.000 description 1
- DIQDKUNCSVFGHH-UHFFFAOYSA-N n-[[4-[[(4-aminoquinazolin-2-yl)amino]methyl]cyclohexyl]methyl]naphthalene-1-sulfonamide;hydrochloride Chemical compound Cl.C1=CC=C2C(N)=NC(NCC3CCC(CNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)CC3)=NC2=C1 DIQDKUNCSVFGHH-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- CYZJKENQGYLGQC-UHFFFAOYSA-N oxadiazole-4,5-dione Chemical class O=C1ON=NC1=O CYZJKENQGYLGQC-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000016438 regulation of fat cell differentiation Effects 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 108091008012 small dense LDL Proteins 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ZAOPBCHLHBOUPR-UHFFFAOYSA-N tert-butyl 1-[2-[di(propan-2-yl)amino]ethylcarbamoyl]-6-phenylmethoxy-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C=1C=C2C(C(=O)NCCN(C(C)C)C(C)C)N(C(=O)OC(C)(C)C)CCC2=CC=1OCC1=CC=CC=C1 ZAOPBCHLHBOUPR-UHFFFAOYSA-N 0.000 description 1
- GISPJYJZCWTSBA-UHFFFAOYSA-N tert-butyl-(3-methoxypropoxy)-diphenylsilane Chemical compound COCCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C GISPJYJZCWTSBA-UHFFFAOYSA-N 0.000 description 1
- 229950004704 tesaglitazar Drugs 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 229950004514 torcetrapib Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10308355A DE10308355A1 (de) | 2003-02-27 | 2003-02-27 | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
PCT/EP2004/001586 WO2004076428A1 (de) | 2003-02-27 | 2004-02-19 | 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006519199A true JP2006519199A (ja) | 2006-08-24 |
Family
ID=32920629
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006501892A Pending JP2006519199A (ja) | 2003-02-27 | 2004-02-19 | 2型糖尿病およびアテローム性動脈硬化症の治療のためのpparモジュレーターとしての4−(3−(2−フェニル−オキサゾール−4−イルメトキシ)−シクロヘキシルオキシ)−ブタン酸誘導体および関連化合物 |
JP2006501885A Pending JP2006519193A (ja) | 2003-02-27 | 2004-02-19 | 2型糖尿病およびアテローム性動脈硬化症の治療のためのpparモジュレーターとしての3−メチル−2−(3−(2−フェニル−オキサゾール−4−イルメトキシ)−シクロヘキサンカルボニル−アミノ酪酸誘導体および関連化合物 |
JP2006501886A Pending JP2006519194A (ja) | 2003-02-27 | 2004-02-19 | 2型糖尿病およびアテローム性動脈硬化症の治療のためのpparモジュレーターとしての3−(2−フェニル−オキサゾール−4−イルメトキシ)シクロヘキシルメトキシ酢酸誘導体および関連化合物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006501885A Pending JP2006519193A (ja) | 2003-02-27 | 2004-02-19 | 2型糖尿病およびアテローム性動脈硬化症の治療のためのpparモジュレーターとしての3−メチル−2−(3−(2−フェニル−オキサゾール−4−イルメトキシ)−シクロヘキサンカルボニル−アミノ酪酸誘導体および関連化合物 |
JP2006501886A Pending JP2006519194A (ja) | 2003-02-27 | 2004-02-19 | 2型糖尿病およびアテローム性動脈硬化症の治療のためのpparモジュレーターとしての3−(2−フェニル−オキサゾール−4−イルメトキシ)シクロヘキシルメトキシ酢酸誘導体および関連化合物 |
Country Status (34)
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
US7399777B2 (en) * | 2001-08-31 | 2008-07-15 | Sanofi-Aventis Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals |
DE10308353A1 (de) * | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102004038403B4 (de) * | 2004-08-07 | 2006-08-31 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten |
DE102004039532B4 (de) * | 2004-08-14 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
DE102004039509B4 (de) | 2004-08-14 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102004039533B4 (de) | 2004-08-14 | 2006-09-28 | Sanofi-Aventis Deutschland Gmbh | Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
DE102004060227B3 (de) * | 2004-12-15 | 2006-07-20 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten |
GT200600218A (es) * | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
EP2052728B1 (en) | 2006-08-10 | 2018-06-13 | mimozax Co., Ltd. | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia |
CN105732376A (zh) | 2007-08-16 | 2016-07-06 | 索尔维公司 | 制备4-氟取代的3-氧代-烷酸酯的方法 |
WO2009107799A1 (ja) * | 2008-02-29 | 2009-09-03 | 日産化学工業株式会社 | チオフェン化合物及びその中間体の製造方法 |
US7615661B2 (en) * | 2008-03-12 | 2009-11-10 | International Flavors & Fragrances Inc. | Thioester compounds and their use in fragrance or flavor applications |
CN116184785A (zh) | 2017-12-13 | 2023-05-30 | 佳能株式会社 | 盒与图像形成装置 |
CN109810071B (zh) * | 2019-03-28 | 2023-04-21 | 中国科学院成都生物研究所 | 一种miRNA生物合成抑制剂 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999046232A1 (fr) * | 1998-03-10 | 1999-09-16 | Ono Pharmaceutical Co., Ltd. | Derives d'acide carboxylique et medicaments contenant ces derives comme principe actif |
WO2002016633A2 (en) * | 2000-08-11 | 2002-02-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods for identifying inhibitors of ubiquitin-mediated proteolysis of ikb |
WO2002051820A1 (fr) * | 2000-12-25 | 2002-07-04 | Ono Pharmaceutical Co., Ltd. | Composes derives de dihydronaphtalene et medicaments utilisant ces composes comme ingredient actif |
JP2002543065A (ja) * | 1999-04-28 | 2002-12-17 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ppap受容体リガンドとしてのトリアリール酸誘導体 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2663336B1 (fr) | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2663464B1 (fr) | 1990-06-19 | 1992-09-11 | Commissariat Energie Atomique | Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication. |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
JP3144624B2 (ja) | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
AU727775B2 (en) | 1996-01-17 | 2000-12-21 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
PT944648E (pt) | 1996-08-30 | 2007-06-26 | Novo Nordisk As | Derivados do glp-1. |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
EP0958296B1 (en) | 1996-12-31 | 2003-07-30 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
DE19726167B4 (de) * | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
BR9810592A (pt) | 1997-07-16 | 2000-09-12 | Novo Nordisk As | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto |
CO4970713A1 (es) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
MA26634A1 (fr) | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
KR100613175B1 (ko) * | 1998-08-27 | 2006-08-17 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제 |
DE19845405C2 (de) * | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
US6908926B1 (en) | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
EP1173438A1 (en) | 1999-04-16 | 2002-01-23 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
SK15532001A3 (sk) | 1999-04-28 | 2002-06-04 | Aventis Pharma Deutschland Gmbh | Deriváty kyselín s dvoma arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú |
AU4808300A (en) | 1999-04-30 | 2000-11-17 | Neurogen Corporation | 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands |
GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
CA2376919C (en) | 1999-06-18 | 2008-11-04 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
WO2001004146A2 (en) | 1999-07-09 | 2001-01-18 | Cohesion Technologies, Inc. | Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof |
DK1204654T3 (da) | 1999-07-29 | 2003-11-17 | Lilly Co Eli | Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister |
DK1218341T3 (da) | 1999-09-01 | 2005-12-12 | Sanofi Aventis Deutschland | Sulfonylcarboxamid-derivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel |
TW200528436A (en) | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
SE9904413D0 (sv) | 1999-12-03 | 1999-12-03 | Astra Ab | Comminuted form |
EE200200278A (et) | 1999-12-03 | 2003-06-16 | Astrazeneca Ab | (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe kristalne vorm |
CA2400226C (en) | 2000-03-31 | 2007-01-02 | Probiodrug Ag | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
WO2001081327A1 (fr) | 2000-04-25 | 2001-11-01 | Kyorin Pharmaceutical Co., Ltd. | Nouveau cristal stable de derive thiazolidinedione et son procede de production |
CA2407538C (en) | 2000-04-28 | 2007-01-09 | Asahi Kasei Kabushiki Kaisha | Novel bicyclic compounds |
EP1280777B1 (en) | 2000-05-11 | 2005-11-23 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
AU2001264977B2 (en) | 2000-05-30 | 2005-04-14 | Merck & Co., Inc. | Melanocortin receptor agonists |
DE50102147D1 (de) | 2000-06-09 | 2004-06-03 | Aventis Pharma Gmbh | Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
DE10038709A1 (de) | 2000-08-09 | 2002-02-28 | Aventis Pharma Gmbh | Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen |
US6982278B2 (en) | 2000-08-23 | 2006-01-03 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
ATE361283T1 (de) * | 2000-08-23 | 2007-05-15 | Lilly Co Eli | Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten |
TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
AU2002222573A1 (en) | 2000-12-05 | 2002-06-18 | Kyorin Pharmaceutical Co. Ltd. | Substituted carboxylic acid derivatives |
GB0031103D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
AU1609702A (en) | 2000-12-21 | 2002-07-01 | Aventis Pharma Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
BR0207285A (pt) | 2001-02-15 | 2004-02-10 | Pfizer Producs Inc | Agonistas de ppar |
PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
JP2005502600A (ja) * | 2001-06-07 | 2005-01-27 | イーライ・リリー・アンド・カンパニー | ペルオキシソーム増殖因子活性化受容体(ppar)のモジュレーター |
DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
WO2003004458A1 (en) | 2001-07-03 | 2003-01-16 | Biovitrum Ab | New compounds |
FR2827859B1 (fr) | 2001-07-30 | 2005-09-23 | Lipha | Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete |
KR100915108B1 (ko) | 2001-08-31 | 2009-09-03 | 사노피-아벤티스 도이칠란트 게엠베하 | Ppar-활성화제로서의 디아릴사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물 |
WO2003066581A1 (en) | 2002-02-05 | 2003-08-14 | Eli Lilly And Company | Urea linker derivatives for use as ppar modulators |
DE10215908B4 (de) | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel |
IL164249A0 (en) | 2002-04-11 | 2005-12-18 | Aventis Pharma Gmbh | Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use |
DE10225635C1 (de) | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
JP4579681B2 (ja) | 2002-07-09 | 2010-11-10 | ブリストル−マイヤーズ スクイブ カンパニー | 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法 |
US7148246B2 (en) * | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
-
2003
- 2003-02-27 DE DE10308355A patent/DE10308355A1/de not_active Withdrawn
-
2004
- 2004-02-19 WO PCT/EP2004/001579 patent/WO2004076427A1/de active IP Right Grant
- 2004-02-19 EP EP04712494A patent/EP1599453B1/de not_active Expired - Lifetime
- 2004-02-19 EP EP04712503A patent/EP1599455B1/de not_active Expired - Lifetime
- 2004-02-19 JP JP2006501892A patent/JP2006519199A/ja active Pending
- 2004-02-19 CA CA002516620A patent/CA2516620A1/en not_active Abandoned
- 2004-02-19 AT AT04712503T patent/ATE435217T1/de not_active IP Right Cessation
- 2004-02-19 RS YUP-2005/0594A patent/RS20050594A/sr unknown
- 2004-02-19 ES ES04712490T patent/ES2287700T3/es not_active Expired - Lifetime
- 2004-02-19 RU RU2005129995/04A patent/RU2005129995A/ru not_active Application Discontinuation
- 2004-02-19 EP EP04712490A patent/EP1599452B1/de not_active Expired - Lifetime
- 2004-02-19 CN CNB2004800054985A patent/CN100398526C/zh not_active Expired - Fee Related
- 2004-02-19 KR KR1020057015995A patent/KR20050106461A/ko not_active Application Discontinuation
- 2004-02-19 PL PL378130A patent/PL378130A1/pl not_active Application Discontinuation
- 2004-02-19 MX MXPA05008995A patent/MXPA05008995A/es active IP Right Grant
- 2004-02-19 ES ES04712503T patent/ES2329366T3/es not_active Expired - Lifetime
- 2004-02-19 BR BRPI0407907-8A patent/BRPI0407907A/pt not_active IP Right Cessation
- 2004-02-19 KR KR1020057016023A patent/KR20050106462A/ko not_active Application Discontinuation
- 2004-02-19 AU AU2004215673A patent/AU2004215673B2/en not_active Ceased
- 2004-02-19 AU AU2004215677A patent/AU2004215677B2/en not_active Ceased
- 2004-02-19 RU RU2005129992/04A patent/RU2005129992A/ru not_active Application Discontinuation
- 2004-02-19 PL PL378437A patent/PL378437A1/pl not_active Application Discontinuation
- 2004-02-19 JP JP2006501885A patent/JP2006519193A/ja active Pending
- 2004-02-19 KR KR1020057015851A patent/KR20050105492A/ko not_active Application Discontinuation
- 2004-02-19 BR BRPI0407758-0A patent/BRPI0407758A/pt not_active IP Right Cessation
- 2004-02-19 OA OA1200500247A patent/OA13034A/en unknown
- 2004-02-19 DE DE502004009690T patent/DE502004009690D1/de not_active Expired - Lifetime
- 2004-02-19 AT AT04712494T patent/ATE430738T1/de not_active IP Right Cessation
- 2004-02-19 AU AU2004215672A patent/AU2004215672B2/en not_active Ceased
- 2004-02-19 PT PT04712490T patent/PT1599452E/pt unknown
- 2004-02-19 MX MXPA05008988A patent/MXPA05008988A/es active IP Right Grant
- 2004-02-19 RU RU2005130002/04A patent/RU2005130002A/ru not_active Application Discontinuation
- 2004-02-19 WO PCT/EP2004/001578 patent/WO2004076426A1/de active Application Filing
- 2004-02-19 BR BRPI0407814-4A patent/BRPI0407814A/pt not_active IP Right Cessation
- 2004-02-19 CA CA002517381A patent/CA2517381A1/en not_active Abandoned
- 2004-02-19 DK DK04712490T patent/DK1599452T3/da active
- 2004-02-19 CN CNB2004800054769A patent/CN100439347C/zh not_active Expired - Fee Related
- 2004-02-19 ES ES04712494T patent/ES2326418T3/es not_active Expired - Lifetime
- 2004-02-19 PL PL377735A patent/PL377735A1/pl not_active Application Discontinuation
- 2004-02-19 WO PCT/EP2004/001586 patent/WO2004076428A1/de active Application Filing
- 2004-02-19 DK DK04712494T patent/DK1599453T3/da active
- 2004-02-19 CA CA002517386A patent/CA2517386A1/en not_active Abandoned
- 2004-02-19 DK DK04712503T patent/DK1599455T3/da active
- 2004-02-19 JP JP2006501886A patent/JP2006519194A/ja active Pending
- 2004-02-19 AT AT04712490T patent/ATE365159T1/de not_active IP Right Cessation
- 2004-02-19 CN CNB2004800054379A patent/CN100439345C/zh not_active Expired - Fee Related
- 2004-02-19 PT PT04712494T patent/PT1599453E/pt unknown
- 2004-02-19 PT PT04712503T patent/PT1599455E/pt unknown
- 2004-02-19 OA OA1200500248A patent/OA13035A/en unknown
- 2004-02-19 DE DE502004009453T patent/DE502004009453D1/de not_active Expired - Lifetime
- 2004-02-19 MX MXPA05008951A patent/MXPA05008951A/es active IP Right Grant
- 2004-02-19 DE DE502004004139T patent/DE502004004139D1/de not_active Expired - Lifetime
- 2004-02-25 TW TW093104705A patent/TW200510352A/zh unknown
- 2004-02-25 TW TW093104704A patent/TW200500349A/zh unknown
- 2004-02-25 TW TW093104697A patent/TW200508210A/zh unknown
- 2004-02-27 AR ARP040100635A patent/AR043432A1/es not_active Application Discontinuation
- 2004-02-27 AR ARP040100629A patent/AR043427A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000206A patent/PE20040959A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000203A patent/PE20050292A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000205A patent/PE20050293A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400392A patent/CL2004000392A1/es unknown
- 2004-02-27 AR ARP040100636A patent/AR043433A1/es not_active Application Discontinuation
- 2004-02-27 US US10/788,997 patent/US7365084B2/en not_active Expired - Fee Related
- 2004-02-27 CL CL200400391A patent/CL2004000391A1/es unknown
- 2004-02-27 US US10/788,996 patent/US7259177B2/en active Active
- 2004-02-27 UY UY28210A patent/UY28210A1/es unknown
- 2004-02-27 PA PA20048596801A patent/PA8596801A1/es unknown
- 2004-02-27 US US10/789,017 patent/US7335671B2/en active Active
- 2004-02-27 UY UY28209A patent/UY28209A1/es unknown
- 2004-06-09 SA SA04250153A patent/SA04250153A/ar unknown
-
2005
- 2005-07-19 ZA ZA200505765A patent/ZA200505765B/en unknown
- 2005-07-19 ZA ZA200505768A patent/ZA200505768B/en unknown
- 2005-08-16 IL IL170314A patent/IL170314A/en not_active IP Right Cessation
- 2005-08-16 IL IL170316A patent/IL170316A/en not_active IP Right Cessation
- 2005-08-26 TN TNP2005000206A patent/TNSN05206A1/en unknown
- 2005-08-26 MA MA28460A patent/MA27737A1/fr unknown
- 2005-08-26 TN TNP2005000204A patent/TNSN05204A1/en unknown
- 2005-08-26 EC EC2005005985A patent/ECSP055985A/es unknown
- 2005-08-26 EC EC2005005986A patent/ECSP055986A/es unknown
- 2005-08-26 HR HR20050744A patent/HRP20050744A2/xx not_active Application Discontinuation
- 2005-08-26 HR HR20050743A patent/HRP20050743A2/xx not_active Application Discontinuation
- 2005-08-26 CO CO05085499A patent/CO5690578A2/es not_active Application Discontinuation
- 2005-08-26 HR HR20050742A patent/HRP20050742A2/xx not_active Application Discontinuation
- 2005-08-26 MA MA28459A patent/MA27736A1/fr unknown
- 2005-08-26 CO CO05085508A patent/CO5690580A2/es not_active Application Discontinuation
- 2005-08-26 MA MA28465A patent/MA27742A1/fr unknown
- 2005-09-22 NO NO20054398A patent/NO20054398L/no unknown
- 2005-09-22 NO NO20054396A patent/NO20054396L/no unknown
- 2005-09-22 NO NO20054408A patent/NO20054408L/no unknown
-
2007
- 2007-08-16 US US11/839,950 patent/US20080015238A1/en not_active Abandoned
-
2008
- 2008-01-14 US US12/013,806 patent/US7872034B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999046232A1 (fr) * | 1998-03-10 | 1999-09-16 | Ono Pharmaceutical Co., Ltd. | Derives d'acide carboxylique et medicaments contenant ces derives comme principe actif |
JP2002543065A (ja) * | 1999-04-28 | 2002-12-17 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ppap受容体リガンドとしてのトリアリール酸誘導体 |
WO2002016633A2 (en) * | 2000-08-11 | 2002-02-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods for identifying inhibitors of ubiquitin-mediated proteolysis of ikb |
WO2002051820A1 (fr) * | 2000-12-25 | 2002-07-04 | Ono Pharmaceutical Co., Ltd. | Composes derives de dihydronaphtalene et medicaments utilisant ces composes comme ingredient actif |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7872034B2 (en) | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | |
US7598281B2 (en) | Arylcycloakyl-substituted alkanoic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes | |
US7160911B2 (en) | Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals | |
US8048901B2 (en) | 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups, processes for their preparation and their use as pharmaceuticals | |
JP2006519196A (ja) | Ppar受容体モジュレーターとしての分枝側鎖を有するアリールシクロアルキル誘導体、その製造方法および医薬としてのその使用 | |
BRPI0611786A2 (pt) | derivados de ácido benzóico substituìdo por 6-oxazol-4-ilmetóxi-alcoximetila formando ligandos de ppar, métodos para produção e o uso dos mesmos na forma de fármacos | |
US7538131B2 (en) | 2-{-3-′2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy}-propionic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes | |
US7956077B2 (en) | 2-{-3,′2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes | |
JP2006519198A (ja) | 生物学的等価体のカルボン酸基を含むシクロアルキル誘導体、その製造方法、及び医薬としてのその使用 | |
US20040220261A1 (en) | Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100622 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101207 |